Genexine focuses on
the research and development of novel drugs.
The weakening of immune surveillance causes the generation of the tumor.
Sensitive immune responses cause immune-related diseases such as autoimmune and hypersensitive disorders.
Pursue therapeutic strategy to hard-to-treat cancers; non-inflamed cold tumors
Suppressive regulation of self-reactive immune responses through immune checkpoint ligand (GX-P1) and combination with immunosuppressive cytokine (GX-P10)
Currently approved drugs for autoimmune diseases mainly target inflammatory cytokines such as anti-TNF. Since these drugs usually focus on alleviating the symptoms, not on the immune cells causing the disease, there are critical unmet needs to improve clinical benefits in non-responders and patients who have relapsed. With GX-P1 and GX-P10, Genexine is pursuing a fundamental approach to the disease-causing immune cells in which the auto-reactive immune cells are controlled by suppressive PD-1/PD-L1 signaling and by additional combination with an immunosuppressive cytokine.